Molecular Mechanism of Targeted Therapy of Chromatin Remodeling Factor ARID1A Mutant Tumors
YANG Shuxian#, CHEN Jiayu#, SUN Xuxu*, WANG Ying*
Chromatin remodeling factor ARID1A (the AT-rich interaction domain 1A) is one of the genes with the highest mutation rate in many types of tumors. ARID1A mutations usually lead to the loss of protein expression and function. Both tumor cells and mouse models with ARID1A mutation proved that ARID1A mutation promoted tumor development, suggesting the malignant role of ARID1A mutation in tumor evolution. The exploration of therapeutic methods and drug targets for ARID1A mutant tumor cells will contribute to the future clinical drug development targeting ARID1A mutant tumors, which has clinical application significance. This paper summarized the latest molecular mechanism and research progress of the synthetic lethal methods and immunotherapy strategies for ARID1A mutant tumors, providing reference for future clinical treatment of ARID1A mutant tumor.
CN
EN